For immediate release
Chicago, IL – December 27, 2021 – Zacks.com announces the list of stocks featured on the Analysts Blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Recent actions featured in the blog include: Tesla, Inc. TSLA, Adobe Inc. ADBE, Merck & Co., Inc. MRK, Edwards Lifesciences Corporation EW, and Norfolk Southern Corporation NSC.
Here are highlights from Thursday’s analyst blog:
Best Stock Reports for Tesla, Adobe and Merck
Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Tesla, Adobe and Merck. These research reports were handpicked from over 70 reports released today by our team of analysts.
You can see all today’s research reports here >>>
Actions of You’re here outperformed Zacks’ domestic auto industry over the past year (+ 52.4% vs. + 19.5%). Zacks analyst believes that strong demand for the Model 3 and Model Y has supported Tesla’s revenue. TSLA hit record levels of production and shipments, despite a chip tightening, in the third quarter of 2021.
Tesla has also started ramping up Model S and Model X volumes. China, being the largest market for electric vehicles, means Tesla’s Shanghai plant is boosting its revenue outlook. Steadily increasing revenues from the automobile as well as from energy production and storage also boosted the earnings outlook.
(You can read the full Tesla research report here >>>)
Adobe stocks have gained + 12.7% over the year-to-date period versus Zacks Software’s industry gain of + 39.1%; however, things seem to be improving. The Zacks analyst believes that Adobe’s Creative Cloud, Document Cloud and Adobe Experience Cloud products drove revenue growth in the fiscal fourth quarter.
Growth in emerging markets, strong demand for online video creation, strong adoption of Acrobat, and improving average revenue per user are some of the key drivers. Adobe’s market leadership, attractive product lines, continuous innovation, strong adoption of Creative Cloud and strong momentum from Workfront are expected to boost its outlook in the quarters to come. Weak end-market demand and high acquisition costs, however, remain a concern.
(You can read the full Adobe research report here >>>)
Actions of Merck have gained + 1.6% in the past six months against Pharmaceuticals Zacks Large Cap’s gain of + 18.2%, but things should improve. The Zacks analyst believes key drugs like Keytruda, Lynparza and Bridion have boosted Merck sales.
Continued adoption in lung cancer and increasing use in other cancer indications have driven sales of Keytruda. Animal health products and vaccines remain the main drivers of growth. Generic competition for several of Merck’s drugs as well as increasing competitive pressure, mainly on the diabetes franchise, remain major concerns, however.
(You can read the full research report on Merck here >>>)
Other noteworthy reports we present today include Edwards Lifesciences and Norfolk Southern Corp.
Zacks investment research
800-767-3771 ext 9339
Past performance is no guarantee of future results. The potential for loss is inherent in any investment. This material is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether an investment is suitable for a particular investor. It should not be assumed that any investment in any identified and described securities, companies, sectors or markets was or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or securities asset management activities. These returns come from hypothetical portfolios composed of stocks with a Zacks rank = 1 that have been rebalanced monthly without any transaction costs. These are not the returns of actual equity portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance numbers displayed in this press release.
Boom in infrastructure stocks will sweep America
A massive push to rebuild crumbling American infrastructure will soon be underway. It is bipartisan, urgent and inevitable. Billions will be spent. Fortunes will be made.
The only question is, “Are you going to jump into good stocks early when they have the greatest potential for growth?” “
Zacks published a special report to help you do just that, and today it’s free. Discover 5 special companies looking to make the most of the construction and repair of roads, bridges and buildings, as well as transporting goods and transforming energy on an almost unimaginable scale.
Download FREE: How to Profit from Billions of Dollars in Infrastructure Spending >>
Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Norfolk Southern Corporation (NSC): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Inventory Analysis Report
Adobe Inc. (ADBE): Free Stock Analysis Report
Tesla, Inc. (TSLA): Free Stock Analysis Report
To read this article on Zacks.com, click here.
Zacks investment research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.